{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:40:09Z","timestamp":1740123609994,"version":"3.37.3"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10875-023-01546-z","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T22:01:45Z","timestamp":1688508105000},"page":"1540-1542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Late-Onset Lymphopenia and ITP in a Patient with Hyper IgM Syndrome Due to a Homozygous Variant in AICDA"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-6529","authenticated-orcid":false,"given":"Adil","family":"Adatia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"issue":"5","key":"1546_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0092-8674(00)00079-9","volume":"102","author":"P Revy","year":"2000","unstructured":"Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102(5):565\u201375.","journal-title":"Cell"},{"issue":"12","key":"1546_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/humu.20414","volume":"27","author":"A Durandy","year":"2006","unstructured":"Durandy A, Peron S, Taubenheim N, Fischer A. Activation-induced cytidine deaminase: structure-function relationship as based on the study of mutants. Hum Mutat. 2006;27(12):1185\u201391.","journal-title":"Hum Mutat"},{"issue":"6","key":"1546_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/1744666X.2023.2198208","volume":"19","author":"B Fevang","year":"2023","unstructured":"Fevang B. Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives. Expert Rev Clin Immunol. 2023;19(6):627\u201338.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"1546_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s10875-016-0282-5","volume":"36","author":"M Carrabba","year":"2016","unstructured":"Carrabba M, Barcellini W, Fabio G. Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia. J Clin Immunol. 2016;36(5):434\u20136.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1546_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2003.10.007","volume":"110","author":"P Quartier","year":"2004","unstructured":"Quartier P, Bustamante J, Sanal O, Plebani A, Debre M, Deville A, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol. 2004;110(1):22\u20139.","journal-title":"Clin Immunol"},{"issue":"7","key":"1546_CR6","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","volume":"119","author":"ES Resnick","year":"2012","unstructured":"Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650\u20137.","journal-title":"Blood"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01546-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01546-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01546-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T08:09:29Z","timestamp":1694592569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-023-01546-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":6,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1007\/s10875-023-01546-z","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"type":"print","value":"0271-9142"},{"type":"electronic","value":"1573-2592"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Alberta Research Ethics Board policy is as follows: \u201cWriting a report on a unique or interesting clinical case would not fall within the definition of research requiring REB review per the second edition of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2)\u201d. Ethics approval was thus not needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"AA reports conference travel support and honararia from Takeda and BioCryst, outside of the submitted work.BR reports grants from Ionis, CSL-Behring, Takeda, OctaPharma, Alynlam, and Mitsubishi Tanbe and travel support from BioCryst, outside of the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}